Welcome to BioSeeker Group!

Prostate Cancer - A Therapeutic & Competitive Insight

Additional Information

Published Date Jan 5, 2007
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 99
PDF Fact Sheet View Fact Sheet for the report Prostate Cancer - A Therapeutic & Competitive Insight in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

In this report BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Prostate Cancer - A Therapeutic & Competitive Insight.

    To find out more about Prostate Cancer - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Prostate Cancer - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Introduction

Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. Several new approvals have changed the panorama for options in the treatment of late stage prostate cancer. Abarelix was approved in November 2003 for the palliative treatment of men with advanced symptomatic prostate cancer. In May 2004 docetaxel was approved for use in combination with prednisone as a treatment for patients with androgen independent (hormone refractory) metastatic prostate cancer. Additionally, in October 2004 FDA approved histrelin for the palliative treatment of advanced prostate cancer. Finally, leuprolide was approved by FDA in January 2002 for the palliative treatment of advanced prostate cancer. One example of market penetration in this field is that analysts forecasts Abarelix a sales of $450 million in 2006.

Research and analysis highlights

In the report "Prostate Cancer - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. In this report, we provide one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase III and II development, together with general descriptions on drugs and targets. We have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

  • Thorough examination of status and impact of several novel drugs in development
  • Discussion of the challenges in current and future treatment strategies
  • Anticancer pipeline of most companies in the field

Key reasons to read this report

  • Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in prostate cancer R&D, and the results of clinical trials to date
  • Gain insight into the current challenges and commercial opportunities associated with prostate cancer therapy
  • One hundred high quality references

Some of the drugs included in this analysis:

toremifene, bevacizumab, oblimersen sodium, R-flurbiprofen, sipuleucel-T, satraplatin, GVAX, exisulind, vapreotide, DCVax-prostate, epothilone D, ixabepilone, PTK/ZK, arsenic trioxide,retinoic acid, imatinib, bortezomib, sorafenib tosylate, doxorubicin etc.

Some of the companies included in this analysis:

Orion Pharma, Genentech, Genta, Encore Pharmaceuticals, Dendreon, Johnson Matthey, Cell Genesys, OSI Pharmaceuticals, Debiopharm, Northwest Biotherapeutics, Kosan Biosciences, Bristol-Myers Squibb, Cephalon, Antigenics, Novartis, Millennium, Bayer, Johnson & Johnson etc

1 Executive Summary

2 Cancer Highlights

3 Methodology

4 4.1 List of Boxes
4.2 List of Tables

5 Introduction
5.1 Disease Definitions
5.2 Etiology & Pathophysiology
5.3 Epidemiology
5.4 Prognosis

6 Current Treatment Strategies
6.1 Localized Disease
6.1.1 Locally Advanced Prostate Cancer
6.2 Metastatic Prostate Cancer
6.2.1 Hormone-Sensitive Metastatic Prostate Cancer
6.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer

7 Progress in Current Treatment Strategies
7.1 Long-Term Follow-up Data not yet Been Published
7.2 Significant Reduced Risk of Distant Metastases
7.3 Adverse Events
7.4 No Difference in Overall Survival
7.5 Cross-over Design an Optimal Option?
7.6 Death due to Liver Failure
7.7 Survival Benefit
7.8 Subdermal Implant
7.9 No FDA Approval
7.10 No Improvement in 5-year Disease-Free Survival
7.11 Effective Secondary Hormonal Therapy?
7.12 Synery in Combination

8 Key Therapeutic Strategies for Future Therapies
8.1 Therapeutic Type, Targets & Mechanisms

9 Competitive Landscape in Drug Development: The Late Stage Pipeline
9.1 Reduced Prostate Cancer Risk
9.2 High Activity in Metastatic AIPC Patients
9.3 Absence of Severe Toxicities
9.4 Waiting for Data
9.5 Probability of Regulatory Approval?
9.6 Co-development and License Agreement
9.7 Improves Predicted Survival?
9.8 Slow Progress & Development Partners
9.9 Exclusive License Agreement

10 Current Drug Development: The Early Stage Pipeline
10.1 New Data?
10.2 Terminated Study
10.3 More Than 50% PSA decline
10.4 Safety and Tolerability
10.5 Terminated
10.6 Marker of Drug Effect
10.7 Preliminary Results for a Tyrosine Kinase Inhibitor
10.8 No Activity in Monotherapy
10.9 Dramatic Disappearance of Bone Metastatic Lesions
10.10 PSA Response - Anthracycline

11 Disclaimer
11.1 Liability
11.2 Completeness

12 Drug Index

13 Company Index

4.1 List of Boxes
Box 1: The Eastern Cooperative Oncology Group Study
Box 2: Southwest Oncology Group Study 99-16 Design
Box 3: TAX 327 Study Design
Box 4: Quick Facts - Toremifene
Box 5: Quick Facts - Bevacizumab
Box 6: Quick Facts - Genasense
Box 7: Quick Facts - R-flurbiprofen
Box 8: Quick Facts - Provenge
Box 9: Quick Facts - Satraplatin
Box 10: Quick Facts - GVAX
Box 11: Quick Facts - Exisulind
Box 12: Quick Facts - Vapreotide
Box 13: Quick Facts - DCVax

4.2 List of Tables
Table 1: The TNM System
Table 2: Lifestyle factors
Table 3: Historical Summary of Clinical Studies on Patients with Late Stage Disease
Table 4: Short Facts Abarelix
Table 5: Short Facts Bicalutamide
Table 6: Short Facts Carboplatin
Table 7: Short Facts Docetaxel
Table 8: Short Facts Mitoxantrone
Table 9: Short Facts Flutamide
Table 10: Short Facts Goserelin
Table 11: Short Facts Histrelin
Table 12: Short Facts Lanreotide
Table 13: Short Facts Leuprolide
Table 14: Short Facts Nilutamide
Table 15: Short Facts Estramustine
Table 16: Summary of Recent Clinical Studies on Patients with Late Stage Disease
Table 17: Ongoing Late Stage Clinical Studies
Table 18: Cancer Immunotherapy Strategies
Table 19: Near Term Progress Toremifene
Table 20: Near Term Progress Bevacizumab
Table 21: Near Term Progress Oblimersen
Table 22: Near Term Progress R-flurbiprofen
Table 23: Near Term Progress APC8015
Table 24: Near Term Progress Satraplatin
Table 25: Near Term Progress GVAX
Table 26: Near Term Progress Exisulind
Table 27: Summary of Prostate Cancer Late Stage Pipeline
Table 28: Paclitaxel
Table 29: Epothilone
Table 30: Ixabepilone
Table 31: PTK/ZK
Table 32: Arsenic trioxide
Table 33: Retinoic Acid
Table 34: Imatinib
Table 35: Bortezomib
Table 36: Sorafenib
Table 37: Doxorubicin
Table 38: Summary of Prostate Cancer Early Stage Pipeline

- Antigenics
- Bayer
- Bristol-Myers Squibb
- Cell Genesys
- Cephalon
- Debiopharm
- Dendreon
- Encore Pharmaceuticals
- Genentech
- Genta
- Johnson & Johnson
- Johnson Matthey
- Kosan Biosciences
- Millennium
- Northwest Biotherapeutics
- Novartis
- Orion Pharma
- OSI Pharmaceuticals
Some of the drugs included in this analysis:
arsenic trioxide,retinoic acid
bevacizumab
bortezomib
DCVax-prostate
doxorubicin
epothilone D
exisulind
GVAX
imatinib
ixabepilone
oblimersen sodium
PTK/ZK
R-flurbiprofen
satraplatin
sipuleucel-T
sorafenib tosylate
toremifene
vapreotide

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Prostate Cancer - A Therapeutic & Competitive Insight.
    To find out more about Prostate Cancer - A Therapeutic & Competitive Insight, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Prostate Cancer - A Therapeutic & Competitive Insight is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Targeted Therapeutics in Non-Small Cell Lung Cancer
With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC. Learn More


Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. Learn More

Other selected research from the 'Oncology' category:


Transcriptional Misregulation in Cancer Drug Pipeline Update
BioSeeker Group have identified 292 companies plus partners who are today developing 350 transcriptional misregulation targeting drugs in 1432 developmental projects in cancer across 229 different targets. In addition, there are 6 suspended drugs and another 204 drugs where development has been ceased. Learn More


Triple Analysis: Apoptosis, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides. Learn More